SG177225A1 - Cancer-related protein kinases - Google Patents

Cancer-related protein kinases Download PDF

Info

Publication number
SG177225A1
SG177225A1 SG2011095569A SG2011095569A SG177225A1 SG 177225 A1 SG177225 A1 SG 177225A1 SG 2011095569 A SG2011095569 A SG 2011095569A SG 2011095569 A SG2011095569 A SG 2011095569A SG 177225 A1 SG177225 A1 SG 177225A1
Authority
SG
Singapore
Prior art keywords
epha2
lmtk2
arg
tyk2
ack1
Prior art date
Application number
SG2011095569A
Other languages
English (en)
Inventor
Axel Ullrich
Jens Ruhe
Stefan Hart
Sylvia Streit
Chee Hong Wong
Boon Tin Chua
Han Kiat Ho
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG177225A1 publication Critical patent/SG177225A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG2011095569A 2006-12-01 2007-12-03 Cancer-related protein kinases SG177225A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86817306P 2006-12-01 2006-12-01

Publications (1)

Publication Number Publication Date
SG177225A1 true SG177225A1 (en) 2012-01-30

Family

ID=39468190

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2011095569A SG177225A1 (en) 2006-12-01 2007-12-03 Cancer-related protein kinases

Country Status (5)

Country Link
US (1) US20110008347A1 (https=)
EP (1) EP2094850B1 (https=)
JP (1) JP2010511382A (https=)
SG (1) SG177225A1 (https=)
WO (1) WO2008066498A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
AU2008206515A1 (en) * 2007-01-11 2008-07-24 Genentech, Inc. Genetic variations associated with tumors
BRPI0816094A2 (pt) 2007-08-30 2015-03-03 Daiichi Sankyo Co Ltd Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
WO2009087462A2 (en) * 2007-12-24 2009-07-16 Oxford Biotherapeutics Ltd. Ephrin type-a receptor 10 protein
BRPI0905948A2 (pt) * 2008-02-05 2015-06-30 Urifer Ltd Sequência de nucleotídeo, sequência de nucleotídeo de interfêrencia curta, composição farmacêutica, método para identificar um estado canceroso em uma célula, kit para identificar um estado canceroso em uma célula, método de tratamento do câncer e polipeptídeo
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
EP2165710A1 (en) 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
EP2169071A1 (en) * 2008-09-29 2010-03-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rodent cancer model for human FGFR4 Arg388 polymorphism
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
JP5439494B2 (ja) * 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
KR101735125B1 (ko) 2008-11-12 2017-05-15 리젠메드 (케이만) 엘티디. 분리된 신장 세포 및 이의 용도
EP3266795A1 (en) 2009-02-12 2018-01-10 Cell Signaling Technology, Inc. Method for detecting a fig-ros fusion polynucleotide
WO2010129503A1 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
EP2336171A1 (en) * 2009-12-11 2011-06-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel targets for the treatment of proliferative diseases
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
CN103154236B (zh) 2010-05-12 2016-08-31 再生医学Tx有限责任公司 生物活性肾细胞
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9587033B2 (en) 2010-11-15 2017-03-07 University Of Florida Research Foundation, Inc. Therapeutic and diagnostic applications targeting TNK-1
ES2657970T3 (es) 2010-12-01 2018-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos contra ROR1 de conejo/ser humano quiméricos
BR112014012979A2 (pt) * 2011-11-30 2020-10-20 Genentech, Inc. mutações erbb3 em câncer
DK3122375T3 (da) 2014-03-28 2021-05-25 Univ Washington Through Its Center For Commercialization Vacciner mod bryst- og ovariecancer
US11946934B2 (en) 2014-09-03 2024-04-02 Wellmarker Bio Co., Ltd. Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof
EP3204510B1 (en) * 2014-10-09 2018-07-25 Roche Diagnostics GmbH Mutations in the epidermal growth factor receptor kinase domain
MA43943A (fr) * 2015-05-29 2018-12-12 Ignyta Inc Compositions et procédés pour traiter des patients avec des cellules mutantes rtk
US10208024B2 (en) 2015-10-23 2019-02-19 Array Biopharma Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
SG11201803098VA (en) 2015-10-30 2018-05-30 Nbe Therapeutics Ag Anti-ror1 antibodies
UA125718C2 (uk) 2016-01-20 2022-05-25 Зе Скріппс Ресеарч Інстітьют Композиції антитіл до ror1 і пов'язані з ними способи
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
CN106480205A (zh) * 2016-11-11 2017-03-08 北京吉因加科技有限公司 用于同时检测多种突变类型的序列组合和探针
KR102718538B1 (ko) 2017-07-19 2024-10-21 이그니타, 인코포레이티드 엔트렉티닙을 포함하는 약학적 조성물
KR20230008269A (ko) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
CN111225662B (zh) 2017-10-17 2022-11-22 伊尼塔公司 药物组合物和剂型
US12077599B2 (en) * 2017-11-29 2024-09-03 Seoul National University R&Db Foundation, National Cancer Center Anti-ROS1 antibody and use thereof
WO2019133752A1 (en) * 2017-12-28 2019-07-04 Development Center For Biotechnology A method for predicting drug efficacy
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
US12351571B2 (en) 2018-12-19 2025-07-08 Array Biopharma Inc. Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
JP7524158B2 (ja) * 2019-03-04 2024-07-29 公益財団法人東京都医学総合研究所 Ｔｒｋ断片をコードする核酸構築物、及びその利用
CN110031626A (zh) * 2019-04-02 2019-07-19 浙江理工大学 一种用于胃肠道间质肿瘤迁移的标志物ack1及其应用
WO2021138392A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Aminopyrimidine compounds
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
KR20230152654A (ko) 2020-12-30 2023-11-03 타이라 바이오사이언시스, 인크. 키나아제 억제제로서의 인다졸 화합물
TW202246243A (zh) 2021-02-26 2022-12-01 美商泰拉生物科學公司 胺基嘧啶化合物及其使用方法
IL317558A (en) 2022-06-29 2025-02-01 Tyra Biosciences Inc Indazole compounds
TW202408493A (zh) 2022-06-29 2024-03-01 美商泰拉生物科學公司 多晶形化合物及其用途
WO2024138112A1 (en) 2022-12-22 2024-06-27 Tyra Biosciences, Inc. Indazole compounds
TW202535368A (zh) 2023-12-15 2025-09-16 美商泰拉生物科學公司 吲唑化合物
WO2025222097A1 (en) 2024-04-19 2025-10-23 Tyra Biosciences, Inc. Indazole-based protac degraders and their anticancer activity
WO2025236094A1 (en) * 2024-05-14 2025-11-20 Narendran Arumugavadivel Identification, design and validation of public neoantigens for the treatment of down syndrome-associated leukemia
WO2026035809A1 (en) 2024-08-06 2026-02-12 Tyra Biosciences, Inc. Indazole compounds for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343940A (en) * 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
DE3069468D1 (en) * 1979-12-19 1984-11-22 Nat Res Dev Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3611194A1 (de) * 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3920029C2 (de) * 1988-06-30 1999-05-20 Clariant Finance Bvi Ltd Farbstoffe zum Färben von Kunststoffen
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SE517975C2 (sv) 2000-05-30 2002-08-13 Power Ab C Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion
WO2002031198A2 (en) * 2000-10-11 2002-04-18 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
US20050191618A1 (en) * 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
WO2003065006A2 (en) * 2002-01-31 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
JP2006174701A (ja) * 2003-02-24 2006-07-06 Research Association For Biotechnology 新規タンパク質およびそれをコードするｄｎａ
JP2005198640A (ja) * 2003-11-25 2005-07-28 Biomarker Science:Kk 遺伝子発現方法

Also Published As

Publication number Publication date
JP2010511382A (ja) 2010-04-15
EP2094850A4 (en) 2010-08-04
WO2008066498A1 (en) 2008-06-05
US20110008347A1 (en) 2011-01-13
EP2094850B1 (en) 2013-06-12
EP2094850A1 (en) 2009-09-02

Similar Documents

Publication Publication Date Title
US20110008347A1 (en) Cancer-related protein kinases
US9364477B2 (en) Mutant ROS expression in human cancer
US20100111944A1 (en) Method of diagnosing, classifying and treating endometrial cancer and precancer
US20100081153A1 (en) Cancer associated protein kinases and their uses
JP6387001B2 (ja) Ｃｄｋ阻害剤と関連するバイオマーカー
Goel et al. The unique N‐terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1
Andrés-Pons et al. In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN
CN100578227C (zh) 用于诊断和作为癌症治疗靶标的ttk
US9464313B2 (en) Biosensor for detecting RAF/KSR family kinase dimerization and uses thereof
US20190094229A1 (en) Methods of diagnosing, classifying and treating endometrial cancer and precancer
CN117795340A (zh) 生物标志物及其用途
WO2012075318A2 (en) Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer
Montecchini TERAPIA DI PRECISIONE PER LA LEUCEMIA LINFOBLASTICA ACUTA PEDIATRICA BCR-ABL-LIKE: SVILUPPO DI UN SISTEMA IN VITRO PER LA DIAGNOSI E IL MONITORAGGIO CLINICO
Mayoral-Varo et al. Pharmacological Modulation of TRIB2 Stability in Melanoma Reveals CDK12/13 as Dominant Regulators and Potential Therapeutic Targets
Shillingford Insights into the Allosteric Regulation and Exploitation of the MAPK Phosphatases as Therapeutic Targets
Montecchini et al. A novel peptide biosensor for screening ABL1 activity in vitro: a challenge for precision therapy in BCR-ABL1 and BCR-ABL1 like leukemias.
Mutic Effect of MAPK inhibition on cell cycle regulation of thymidine kinase 1 and [18F]-FLT PET
AU2007237228A1 (en) Cancer associated protein kinases and their uses
HK1210482B (en) Mutant ros expression in human liver cancer
JP2005245403A (ja) アポトーシス調節活性を測定する方法、及びアポトーシス調節活性を有する化合物のスクリーニング方法
HK1165007B (en) Mutant ros expression in human liver cancer